GNI Group (2160) · RiskFirst statedLatest Other Disclosures (2026-03-13): "Restated"
Expiry of the regulatory protection period for Aisuuryui (pirfenidone) in China and intensifying competition
First written in FY2017. 1 of 2 entries say "Restated". Latest entry: 2026-03-13.
2entries
9years
1from disclosures
How it moved
Same theme, other companies
Intensifying competition following the expiry of regulatory protection for Eisurei (pirfenidone) in ChinaA theme 1 companies write about · 1 as a headwind · 0 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- 2026-03-13RestatedOther Disclosures
「For the pulmonary fibrosis treatment ETUARY® (Iusurui), Gyre expects to maintain revenue of approximately $100 million, provided that generic products do not enter the market in the near future.」
The company presented a forecast that Iusurui revenue would be maintained subject to the absence of generic competition, explicitly identifying the competitive-risk assumption. - FY2017First statedAnnual report
「当社グループの主力医薬品であるIPF治療薬アイスーリュイへの中国規制当局による保護は2019年に期限切れを迎えるため、近い将来、他のIPF治療法や潜在的な後発医薬品との競争に直面する可能性があります。」
中国におけるアイスーリュイへの規制当局の保護が2019年に期限切れとなり、他の治療法や後発医薬品との競争に直面する可能性を示している。